Depression in Alzheimer’s Disease Study - 2
Home About DIADS-2 About CC Contact Us  

The Depression in Alzheimer’s Disease Study-2 was a randomized, placebo-controlled, multi-center trial designed to evaluate the efficacy and safety of sertraline for the treatment of depression in patients with Alzheimer’s disease.  Sertraline was tested in parallel at a target dose of 100 mg b.i.d. (range 25-125 mg b.i.d.) against a matched placebo.  The trial enrolled 131 participants who meet criteria for depression of Alzheimer’s disease.  Participants were evaluated with structured, standardized methods of diagnosis and assessment.

DIADS-2 datasets are available upon request. All requests must be vetted by the DIADS-2 Steering Committee and must include a detailed analysis proposal and proof of IRB approval for the proposed project. Requests can be submitted to the address provided in the Contacts page of this website.


Last Updated:

02 Feb 2012
© DIADS-2 Coordinating Center